p38 mitogen activated protein kinase as a therapeutic target for Alzheimer's disease

Journal of Molecular Neuroscience

Volumn 19, Issue 3, 2002, Pages 295-299

  Dalrymple, Stacie A ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Alzheimer's disease; MAP kinase (MAPK); Neurofibrillary tangles (NFTs); P38; Tau

Indexed keywords

AMYLOID BETA PROTEIN; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; TAU PROTEIN;

ALZHEIMER DISEASE; CHOLINERGIC ACTIVITY; CLINICAL FEATURE; COGNITION; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; INFLAMMATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOLOGY; PHARMACOLOGICAL BLOCKING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SENILE PLAQUE;

ALZHEIMER DISEASE; ANIMALS; HUMANS; INFLAMMATION; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROFIBRILLARY TANGLES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; TAU PROTEINS;

EID: 0036922447     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:19:3:295     Document Type: Review

References (37)

1. Aisen P. S., Davis K. L., Berg J. D., Schafer K., Campbell K., Thomas R. G., et al. (2000) A randomized controlled trial of prednisone in Alzheimer's disease. Neurology 54, 588-593.
2. Anderton B. H., Betts J., Blackstock W. P., Brion J. P., Chapman S., Connell J., et al. (2001) Sites of phosphorylation in tau and factors affecting their regulation. Biochem. Soc. Symp. 67, 73-80.
3. Atzori C., Ghetti B., Piva R., Srinivasan A. N., Zolo P., Delisle M. B., et al. (2001) Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J. Neuropathol. Exp. Neurol. 60, 1190-1197.
4. Badger A. M., Bradbeer J. N., Votta B., Lee J. C., Adams J. L., and Griswold D. E. (1996) Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Therap. 279, 1453-1461.
5. Barone F. C., Irving E. A., Ray A. M., Lee J. C., Kassis S., Kumar S., et al. (2001) Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med. Res. Rev. 21, 129-145.
6. Branger J., van den Blink B., Weijer S., Madwed J., Bos C. L., Gupta A., et al. (2002) Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J. Immunol. 168, 4070-4077.
7. Buee-Scherrer V. and Goedert M. (2002) Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells. FEBS Lett. 515, 151-154.
8. Chartier-Harlin M. C., Crawford F., Houlden H., Warren A., Hughes D., Fidani L., et al. (1991) Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 353, 844-846.
9. Esler W. P. and Wolfe M. S. (2001) A portrait of Alzheirmer secretases - New features and familiar faces. Science 293, 1449-1454.
10. Ferrer I., Blanco R., Carmona M., and Puig B. (2001) Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J. Neural Transm. 108, 1397-1415.
11. Fijen J. W., Zijlstra J. G., De Boer P., Spanjersberg R., Cohen Tervaert J. W., Van der Werf T. S., et al. (2001) Suppression of the clinical and cyotkine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin. Exp. Immunol. 124, 16-20.
12. Goate A., Chartier-Harlin M. C., Mullan M., Brown J., Crawford F., Fidani L., et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706.
13. Goedert M., Hasegawa M., Jakes R., Lawler S., Cuenda A., and Cohen P. (1997) Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett. 409, 57-62.
14. Hensley K., Floyd R. A., Zheng N. Y., Nael R., Robinson K. A., Nguyen X., et al. (1999) p38 kinase is activated in the Alzheimer's disease brain. J. Neurochem. 72, 2053-2058.
15. Herlaar E. and Brown Z. (1999) p38 MAPK signalling cascades in inflammatory disease. Mol. Med. Today 5, 439-447.
16. Hull M., Lieb K., and Fiebich B. L. (2002) Pathways of inflammatory activation in Alzheimer's disease: Potential targets for disease modifying drugs. [review]. Curr. Med. Chem. 9, 83-88.
17. In't Veld B. A., Ruitenberg A., Hofman A., Launer L. J., van Duijn C. M., Stijnen T., et al. (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 345, 1515-1521.
18. Ishihara T., Hong M., Zhang B., Nakagawa Y., Lee M. K., Trojanowski J. Q., and Lee V. M. (1999) Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24, 751-762.
19. Ishihara T., Zhang B., Higuchi M., Yoshiyama Y., Trojanowski J. Q., and Lee V. M. (2001) Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. Am. J. Pathol. 158, 555-562.
20. Jackson J. R., Bolognese B., Hillegass L., Kassis S., Adams J., Griswold D. E., et al. (1998) Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J. Pharmacol. Exp. Ther. 284, 687-692.
21. Lee J. C., McDonnell P. C., Gallagher T. F., Kumar S., Green D., McNulty D., et al. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739-746.
22. Levy-Lahad E., Wasco W., Poorkaj P., Romano D. M., Oshima J., Pettingell W. H., et al. (1995) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973-977.
23. Lewis J., Dickson D. W., Lin W.-L., Chrisholm L., Corral A., Jones G., et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant Tau and APP. Science 293, 1487-1491.
24. McDonald D. R., Bamberger M. E., Combs C. K., and Landreth G. E. (1998) Beta-amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. J. Neurosci. 18, 4451-4460.
25. McGeer P. L. and McGeer E. G. (2001) Polymorphisms in inflammatory genes and the risk of Alzheimer disease. Arch. Neurol. 58, 1790-1792.
26. Murrell J., Farlow M., Ghetti B., and Benson M. D. (1991) A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 254, 97-99.
27. Nagy Z., Esiri M. M., Jobst K. A., Morris J. H., King E. M., McDonald B., et al. (1995) Relative roles of plaques and tangles in the dementia of Alzheimer's disease: Correlations using three sets of neuropathological criteria. Dementia 6, 21-31.
28. Naslund J., Haroutunian V., Mohs R., Davis K. L., Davies P., Greengard P., et al. (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283, 1571-1577.
29. Reynolds C. H., Nebreda A. R., Gibb G. M., Utton M. A., and Anderton B. H. (1997) Reactivating kinase/p38 phosphorylates tau protein in vitro. J. Neurochem. 69, 191-198.
30. Reynolds C. H., Betts J. C., Blackstock W. P., Nebreda A. R., and Anderton B. H. (2000) Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: Differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J. Neurochem. 74, 1587-1595.
31. Rogaev E. I., Sherrington R., Rogaeva E. A., Levesque G., Ikeda M., Liang Y., et al. (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376, 775-778.
32. Sainati S. (2000) Study Shows Celecoxib Not Useful in Preventing Alzheimer's Dementia: Johnston, C./DG DISPATCH - ISSSAT, (press release).
33. Savage M. J., Lin Y.-G., Ciallella J. R., Flood C. G., and Scott R. W. (2002) Activation of c-jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J. Neurosci. 22, 3376-3385.
34. Sheng J. G., Ito K., Skinner R. D., Mrak R. E., Rovnaghi C. R., Van Eldik L. J., et al. (1996) In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol. Aging 17, 761-766.
35. Sheng J. G., Jones R. A., Zhou X. Q., McGinness J. M., Van Eldik L. J., Mrak R. E., et al. (2001) Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: Potential significance for tau protein phosphorylation. Neurochem. Int. 39, 341-348.
36. Sherrington R., Rogaev E. I., Liang Y., Rogaeva E. A., Levesque G., Ikeda M., et al. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754-760.
37. Zhu X., Rottkamp C. A., Boux H., Takeda A., Perry G., and Smith M. A. (2000) Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-r elated events in Alzheimer disease. J. Neuropathol. Exp. 59, 880-888.